Influence of vitreomacular interface score on treatment outcomes of anti-VEGF therapy for neovascular age-related macular degeneration

Table 3 Comparison between complete PVD and the other

	Complete PVD	The other	P-value
Eyes, n (patients, n)	43 (43)	16 (16)
Age, years	75.7 ± 7.3	70.7 ± 8.3	0.03*
Sex (M/F), n	29/14	12/4	0.58^†
Subtype (tAMD/PCV)	20/23	10/6	0.28^†
Axial length, mm	23.81 ± 0.88	23.54 ± 1.01	0.31
LogMAR BCVA
Baseline	0.32 ± 0.34	0.16 ± 0.25	0.10
1 year after treatment	0.22 ± 0.38	0.06 ± 0.24	0.11
Change during 1 year	− 0.08 ± 0.25	− 0.15 ± 0.31	0.37
Central retinal thickness at baseline, μm	275.4 ± 115.1	293.9 ± 112.0	0.58
Subfoveal choroidal thickness at baseline, μm	206.2 ± 93.9	300.5 ± 127.6	0.003*
1-year retinal exudate status (wet/dry)	11/32	1/15	0.10^†
Genotype, n
ARMS2 A69S (GG/GT/TT)	8/19/14^a	3/7/6	0.14^‡
CFH I62V (AA/AG/GG)	4/20/17^b	2/10/4	0.42^‡

Data are presented as means ± standard deviations where applicable
PVD, posterior vitreous detachment; tAMD, typical age-related macular degeneration; PCV, polypoidal choroidal vasculopathy; logMAR BCVA, logarithm of the minimal angle of resolution best-corrected visual acuity; ARMS2, age-related maculopathy susceptibility protein 2; and CFH, complement factor H
In ARMS2 A69S, GG, GT, and TT represent non-risk-homo, hetero, and risk-homo, respectively
In CFH I62V, AA, AG, and GG represent non-risk-homo, hetero, and risk-homo, respectively
In measurements indicated by ^a and ^b data are missing for two and two patients, respectively
^†Chi-square test
^‡Chi-square trend test; the remaining: t-test
*Statistically significant (P < 0.05)

ISSN: 2056-9920